Insider Selling: Revvity (NYSE:RVTY) Insider Sells 1,631 Shares of Stock

Revvity Inc. (NYSE:RVTY) insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Revvity Stock Performance

Shares of Revvity stock traded down $1.08 during trading on Wednesday, hitting $142.23. 2,244,322 shares of the stock were exchanged, compared to its average volume of 1,470,828. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 67.73, a price-to-earnings-growth ratio of 2.61 and a beta of 1.09. The company has a fifty day moving average price of $121.92 and a 200-day moving average price of $105.43. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $149.52. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. During the same quarter last year, the company posted $1.18 earnings per share. Revvity’s quarterly revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently added to or reduced their stakes in the stock. Ascentis Independent Advisors acquired a new position in Revvity during the 1st quarter worth approximately $29,000. SJS Investment Consulting Inc. boosted its position in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Revvity during the second quarter worth $51,000. Summit Securities Group LLC increased its holdings in shares of Revvity by 294.6% during the first quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock worth $58,000 after buying an additional 495 shares in the last quarter. Finally, Contravisory Investment Management Inc. bought a new position in shares of Revvity in the 1st quarter valued at $66,000. Institutional investors own 86.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. TD Cowen reissued a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Evercore reaffirmed an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Finally, Wolfe Research began coverage on Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat.com, Revvity currently has an average rating of “Hold” and a consensus target price of $116.57.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.